Jupiter's de Blonay: The financials phoenix is rising again

clock

Like a phoenix rising from the ashes, the battered financials sector is back to delivering double-digit returns after having its wings severely clipped by the financial crisis.

In the 12 months to end October, the benchmark MSCI ACWi/Financials Index (Gross TR in GB) is up 13.2% compared to a gain of 15.9% for the S&P 500 and a rise of 6.7% for the FTSE 100. Helping drive these gains, a powerful revolution in the way payments are being made across the global economy. Rising credit card use, the growing dominance of e-commerce and the emergence of mobile payment technology are putting paid to the idea that cash is king. This global trend is a boon for credit card giants like Visa and MasterCard. Growth in these businesses is being underpinned by expanding con...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Specialist

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

‘Dedicated specialists’

James Baxter-Derrington
clock 06 April 2023 • 4 min read
European private equity yet to spend €270bn worth of capital

European private equity yet to spend €270bn worth of capital

Deployment of capital expected

Kathleen Gallagher
clock 04 January 2023 • 1 min read
Early-stage biopharma: An opportunity for strategic investment

Early-stage biopharma: An opportunity for strategic investment

Disproportionately smaller investment

Ali H. Munawar
clock 10 August 2022 • 4 min read
Trustpilot